Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement

Author's Avatar
Nov 03, 2020
Article's Main Image

Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% Convertible Senior Notes due 2025 (the “notes”) through a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Novocure also granted the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $75 million aggregate principal amount of notes. The offering is expected to close on November 5, 2020, subject to customary closing conditions.